NCT06854653 - A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions

CTCL

Interventions

DRUG

PTX-100

Peptidomimetic inhibitor of GGTase 1

Trial Locations (16)

2145

RECRUITING

Westmead Hospital, Westmead

3002

RECRUITING

Epworth Healthcare, Melbourne

6009

RECRUITING

Linear Clinical Research, Nedlands

14642

NOT_YET_RECRUITING

Rochester Skin Lymphoma Medical Group. PLLC, Rochester

20132

NOT_YET_RECRUITING

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele), Milan

25123

NOT_YET_RECRUITING

Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia

33000

NOT_YET_RECRUITING

CHU de Bordeaux - Hopital Saint André, Bordeaux

33612

NOT_YET_RECRUITING

Moffitt Cancer Center, Tampa

40138

NOT_YET_RECRUITING

IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Bologna

69310

NOT_YET_RECRUITING

Hopital Lyon Sud, Lyon

75010

NOT_YET_RECRUITING

Hopital Saint Louis, Paris

91010

RECRUITING

City of Hope Comprehensive Cancer Cente, Duarte

92697

NOT_YET_RECRUITING

University of California Irvine, Irvine

980037

RECRUITING

Virginia Commonwealth University Massey Comprehensive Cancer Cente, Richmond

06510

NOT_YET_RECRUITING

Yale Cancer Center, New Haven

022155450

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston